

<b>DRUG:</b>	<b>SURFACTANT (BOVINE) – BERACTANT (SURVANTA)</b>
<b>PRESENTATION:</b>	Vial: 8 mL
<b>ACTION &amp; INDICATION:</b>	Pulmonary surfactant derived from natural bovine lung extract and used for the prevention or treatment of respiratory distress syndrome, according to NCCU guidelines.
<b>DOSE:</b>	4 mL/kg/dose Up to four doses may be administered, at 6 hourly intervals.
<b>ADMINISTRATION:</b>	<b>For intratracheal administration only.</b> Survanta is administered via a 5fg end hole catheter shortened to protrude just beyond the end of the ETT, above the carina. Survanta should <b>NOT</b> be instilled into a <b>main</b> stem bronchus. Administer as outlined in the NCCU “Surfactant Replacement Therapy Guidelines”.
<b>ADVERSE EFFECTS:</b>	Adverse effects associated with dosing procedure: Transient bradycardia, oxygen desaturation, ETT reflux, pallor, vasoconstriction, hypotension, ETT blockage, hypertension, hypocarbia, hypercarbia, apnoea.
<b>COMMENTS:</b>	Warm vial to room temperature before use. Do not use artificial warming methods. Do not shake. Store open and unopened vials at 2 - 8°C. Discard 12 hours after opening.  Evaluate clinical condition before and for 30 minutes after each dose
<b>REFERENCES:</b>	Neofax 2008
<b>DATE:</b>	January 2011